US FDA Approves Novartis Skin Treatment Drug Cosentyx
The U.S. FDA has approved Novartis’ drug Cosentyx for treating moderate to severe hidradenitis suppurativa, a chronic inflammatory skin condition.
The U.S. FDA has approved Novartis’ drug Cosentyx for treating moderate to severe hidradenitis suppurativa, a chronic inflammatory skin condition.